Overview

Update
Primary Role
General Partner @
Investments
35 Investments in 14 Companies
Gender:
Female
Location:
San Francisco
Social:

Person Details

Update

Healthcare investor Wende Hutton brings 23 years of experience to identifying, investing in and building companies that are changing the practice of medicine. She has facilitated bringing over a dozen medical devices and drugs to market, and currently sits on the boards of Antiva Biosciences, Chrono Therapeutics, Glooko, OncoResponse, ReVision Optics and Theraclone Sciences. Prior investments include BiPar Sciences (acquired by Sanofi-aventis), Chimerix (CMRX), Dermira (DERM), Labrys Biologics (acquired by Teva Pharmaceutical) and Transcend Medical (acquired by Alcon/Novartis). Wende was recognized among Fierce Biotech’s 2014 "Fierce 15" women in biotech and honored as one of The Most Influential Women in Bay Area Business 2015 by The San Francisco Business Times.

Wende joined Canaan in 2004, and her life sciences track record includes seven IPOs and six acquisitions. She began her venture career at Mayfield Fund in 1993, where she incubated Heartstream (HPQ) and Northstar Neuroscience (NSTR). Earlier in her career, Wende held senior operational management positions at GenPharm International and Nellcor in business development and marketing.

Wende holds an AB in human biology from Stanford University and an MBA from Harvard Business School, where she was a Baker Scholar. She is active with several community service groups including serving on the board of ReSurge International which provides reconstructive surgical care to the needy in developing countries.

Jobs (5)

Update
Current

General Partner

2004 - Current   (over 12 years)
Past
Started
Ended
Title
Company
2001
Unknown
General Partner
1993
2001
General Partner
1991
1992
General Manager, Transgenic Lab Products
1986
1990
Director, International Business Unit; Dir of Business Development; Marketing
DateInvested InRoundDetails
Sep, 2016$8M / Series C (Lead)
Sep, 2016$47.6M / Series B
Nov, 2015$14.12M / Series C (Lead)
Mar, 2015$16.5M / Series B (Lead)
Aug, 2014$24M / Series B
Aug, 2014$51M / Series C
Jun, 2014$6M / Debt Financing
Jun, 2014$32M / Series A (Lead)
Jul, 2013$55M / Series E
Jun, 2013$2.5M / Series B
Jun, 2013$35M / Series B
Apr, 2013$15M / Series E
Apr, 2013$2M / Venture
Mar, 2013$9M / Series B (Lead)
Mar, 2013$8M / Series B
Jan, 2013$31M / Series A
Dec, 2012$14.59M / Venture
Feb, 2012$12.5M / Series A
Jan, 2012$16M / Series B
Oct, 2011$42M / Series A
Feb, 2011$45M / Series F
Jul, 2010$35M / Series D
Apr, 2010$20M / Series A
Mar, 2010$1.5M / Series B
Nov, 2009$1.4M / Venture
Aug, 2009$16.1M / Series E
Jun, 2009$5.9M / Series D
Jun, 2009$35M / Series B
Jan, 2009$20M / Series C
Aug, 2008$35M / Series B (Lead)
Jun, 2007$17M / Series C (Lead)
Mar, 2007$29M / Series B (Lead)
Feb, 2007$35M / Series B
Feb, 2007$23.1M / Series D (Lead)
Dec, 2004$13M / Series A

Education (2)

Update

Add Memberships

Add Images

Add Videos